These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 25978072)
21. 1H-Pyrazolo[3,4-g]hexahydro-isoquinolines as selective glucocorticoid receptor antagonists with high functional activity. Clark RD; Ray NC; Williams K; Blaney P; Ward S; Crackett PH; Hurley C; Dyke HJ; Clark DE; Lockey P; Devos R; Wong M; Porres SS; Bright CP; Jenkins RE; Belanoff J Bioorg Med Chem Lett; 2008 Feb; 18(4):1312-7. PubMed ID: 18226897 [TBL] [Abstract][Full Text] [Related]
22. 1H-Pyrazolo[3,4-g]hexahydro-isoquinolines as potent GR antagonists with reduced hERG inhibition and an improved pharmacokinetic profile. Hunt HJ; Belanoff JK; Golding E; Gourdet B; Phillips T; Swift D; Thomas J; Unitt JF; Walters I Bioorg Med Chem Lett; 2015 Dec; 25(24):5720-5. PubMed ID: 26546213 [TBL] [Abstract][Full Text] [Related]
23. Synthesis and biological evaluation of novel naphthalene compounds as potential antidepressant agents. Ang W; Chen G; Xiong L; Chang Y; Pi W; Liu Y; Li C; Zheng J; Zhou L; Yang B; Deng Y; Yang S; Luo Y; Wei Y Eur J Med Chem; 2014 Jul; 82():263-73. PubMed ID: 24915002 [TBL] [Abstract][Full Text] [Related]
24. Anxiolytic-like and antidepressant-like activities of MCL0129 (1-[(S)-2-(4-fluorophenyl)-2-(4-isopropylpiperadin-1-yl)ethyl]-4-[4-(2-methoxynaphthalen-1-yl)butyl]piperazine), a novel and potent nonpeptide antagonist of the melanocortin-4 receptor. Chaki S; Hirota S; Funakoshi T; Suzuki Y; Suetake S; Okubo T; Ishii T; Nakazato A; Okuyama S J Pharmacol Exp Ther; 2003 Feb; 304(2):818-26. PubMed ID: 12538838 [TBL] [Abstract][Full Text] [Related]
25. Design, Docking, Characterisation, and Synthesis of Pyrimidine Derivatives for Antidepressant Activity. Jadhav A; Shingade SG; Dessai PG; Biradar BS; MamleDesai S Curr Drug Discov Technol; 2024; 21(3):64-72. PubMed ID: 37859311 [TBL] [Abstract][Full Text] [Related]
26. Antidepressant-like effects of mineralocorticoid but not glucocorticoid antagonists in the lateral septum: interactions with the serotonergic system. Mostalac-Preciado CR; de Gortari P; López-Rubalcava C Behav Brain Res; 2011 Sep; 223(1):88-98. PubMed ID: 21515309 [TBL] [Abstract][Full Text] [Related]
27. Antidepressant and antipsychotic activity of new quinoline- and isoquinoline-sulfonamide analogs of aripiprazole targeting serotonin 5-HT₁A/5-HT₂A/5-HT₇ and dopamine D₂/D₃ receptors. Zajdel P; Marciniec K; Maślankiewicz A; Grychowska K; Satała G; Duszyńska B; Lenda T; Siwek A; Nowak G; Partyka A; Wróbel D; Jastrzębska-Więsek M; Bojarski AJ; Wesołowska A; Pawłowski M Eur J Med Chem; 2013 Feb; 60():42-50. PubMed ID: 23279866 [TBL] [Abstract][Full Text] [Related]
28. Synthesis and activity of novel bile-acid conjugated glucocorticoid receptor antagonists. Richards SJ; von Geldern TW; Jacobson P; Wilcox D; Nguyen P; Ohman L; Osterlund M; Gelius B; Grynfarb M; Goos-Nilsson A; Wang J; Fung S; Kalmanovich M Bioorg Med Chem Lett; 2006 Dec; 16(23):6086-90. PubMed ID: 16987661 [TBL] [Abstract][Full Text] [Related]
29. New arylpiperazine 5-HT(1A) receptor ligands containing the pyrimido[2,1-f]purine fragment: synthesis, in vitro, and in vivo pharmacological evaluation. Jurczyk S; Kołaczkowski M; Maryniak E; Zajdel P; Pawłowski M; Tatarczyńska E; Kłodzińska A; Chojnacka-Wójcik E; Bojarski AJ; Charakchieva-Minol S; Duszyńska B; Nowak G; Maciag D J Med Chem; 2004 May; 47(10):2659-66. PubMed ID: 15115407 [TBL] [Abstract][Full Text] [Related]
30. 5-Aryl-1,2-dihydrochromeno[3,4-f]quinolines: a novel class of nonsteroidal human progesterone receptor agonists. Zhi L; Tegley CM; Kallel EA; Marschke KB; Mais DE; Gottardis MM; Jones TK J Med Chem; 1998 Jan; 41(3):291-302. PubMed ID: 9464360 [TBL] [Abstract][Full Text] [Related]
31. Design, synthesis, and structure-activity relationships of a series of 2-Ar-8-methyl-5-alkylaminoquinolines as novel CRF₁ receptor antagonists. Takeda K; Terauchi T; Hashizume M; Shin K; Ino M; Shibata H; Yonaga M Bioorg Med Chem Lett; 2012 Sep; 22(17):5372-8. PubMed ID: 22871582 [TBL] [Abstract][Full Text] [Related]
32. An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression. Becker OM; Dhanoa DS; Marantz Y; Chen D; Shacham S; Cheruku S; Heifetz A; Mohanty P; Fichman M; Sharadendu A; Nudelman R; Kauffman M; Noiman S J Med Chem; 2006 Jun; 49(11):3116-35. PubMed ID: 16722631 [TBL] [Abstract][Full Text] [Related]
33. New directions in the development of antidepressants: the interface of neurobiology and psychiatry. Nemeroff CB Hum Psychopharmacol; 2002 Jun; 17 Suppl 1():S13-6. PubMed ID: 12404664 [TBL] [Abstract][Full Text] [Related]
34. Substituted phenyl as a steroid A-ring mimetic: providing agonist activity to a class of arylsulfonamide nonsteroidal glucocorticoid ligands. DiSalvo D; Kuzmich D; Bentzien J; Regan J; Kukulka A; Fadra-Khan T; Nelson R; Harcken C; Thomson D; Nabozny G Bioorg Med Chem Lett; 2013 Dec; 23(24):6645-9. PubMed ID: 24239189 [TBL] [Abstract][Full Text] [Related]
35. Synthesis and SAR of 2-aryloxy-4-alkoxy-pyridines as potent orally active corticotropin-releasing factor 1 receptor antagonists. Chen YL; Braselton J; Forman J; Gallaschun RJ; Mansbach R; Schmidt AW; Seeger TF; Sprouse JS; Tingley FD; Winston E; Schulz DW J Med Chem; 2008 Mar; 51(5):1377-84. PubMed ID: 18260619 [TBL] [Abstract][Full Text] [Related]
36. Discovery of a novel 5-HT(3) antagonist/5-HT(1A) agonist 3-amino-5,6,7,8-tetrahydro-2-{4-[4-(quinolin-2-yl)piperazin-1-yl]butyl}quinazolin-4(3H)-one (TZB-30878) as an orally bioavailable agent for irritable bowel syndrome. Asagarasu A; Matsui T; Hayashi H; Tamaoki S; Yamauchi Y; Minato K; Sato M J Med Chem; 2010 Nov; 53(21):7549-63. PubMed ID: 20931963 [TBL] [Abstract][Full Text] [Related]
37. The extracellular entrance provides selectivity to serotonin 5-HT7 receptor antagonists with antidepressant-like behavior in vivo. Medina RA; Vázquez-Villa H; Gómez-Tamayo JC; Benhamú B; Martín-Fontecha M; de la Fuente T; Caltabiano G; Hedlund PB; Pardo L; López-Rodríguez ML J Med Chem; 2014 Aug; 57(15):6879-84. PubMed ID: 25073094 [TBL] [Abstract][Full Text] [Related]
38. Discovery and optimisation of a selective non-steroidal glucocorticoid receptor antagonist. Brown AR; Bosies M; Cameron H; Clark J; Cowley A; Craighead M; Elmore MA; Firth A; Goodwin R; Goutcher S; Grant E; Grassie M; Grove SJ; Hamilton NM; Hampson H; Hillier A; Ho KK; Kiczun M; Kingsbury C; Kultgen SG; Littlewood PT; Lusher SJ; Macdonald S; McIntosh L; McIntyre T; Mistry A; Morphy JR; Nimz O; Ohlmeyer M; Pick J; Rankovic Z; Sherborne B; Smith A; Speake M; Spinks G; Thomson F; Watson L; Weston M Bioorg Med Chem Lett; 2011 Jan; 21(1):137-40. PubMed ID: 21129964 [TBL] [Abstract][Full Text] [Related]
39. In vitro antiprogestational/antiglucocorticoid activity and progestin and glucocorticoid receptor binding of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and mifepristone. Attardi BJ; Burgenson J; Hild SA; Reel JR J Steroid Biochem Mol Biol; 2004 Mar; 88(3):277-88. PubMed ID: 15120421 [TBL] [Abstract][Full Text] [Related]
40. Discovery of novel phosphorus-containing steroids as selective glucocorticoid receptor antagonist. Jiang W; Fiordeliso JJ; Allan G; Linton O; Tannenbaum P; Xu J; Zhu P; Gunnet J; Demarest K; Lundeen S; Sui Z Bioorg Med Chem Lett; 2007 Mar; 17(5):1471-4. PubMed ID: 17258455 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]